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TO THE EDITOR
Primary cutaneous lymphomas are
characterized by the localization of
malignant lymphocytes to the skin at
presentation (Willemze et al., 2005). In
mycosis fungoides (MF), conventional
PCR of peripheral blood (PB) have
demonstrated the presence of mono-
clonal T cells in all stages, although less
often in early disease (Delfau-Larue
et al., 2000; Muche et al., 1997,
2003). MF is generally assumed to spare
bone marrow (BM) until advanced
stage, as evidenced by histopathology
(Sausville et al., 1988; Marti et al.,
1996); however, limited information is
available on molecular staging in BM
(Veelken et al., 1995; Sandberg et al.,
2003; Sibaud et al., 2003). The pre-
sence of malignant T cells in extracuta-
neous compartments in early-stage MF
is suggestive of a systemic nature
(Muche et al., 1997). If this is true, the
question arises whether it is possible to
detect minimal extracutaneous involve-
ment in patients diagnosed with local
disease by clinicopathology and con-
ventional clonality assays. To answer
this, 11 patients (two female, nine male,
average age: 64.9 years) with clinically
and histologically confirmed MF stage
IA–IIB were included in this study.
Extracutaneous samples were histologi-
cally uninvolved. Diagnosis of MF was
based on the EORTC (European Orga-
nization for Research and Treatment of
Cancer) classification for primary cuta-
neous lymphoma (Willemze et al.,
1997). BM biopsy was carried out for
routine staging of MF in all patients
regardless of the clinical stage of the
disease. DNA from skin, PB, and BM
was analyzed for the presence of TCRg
and TCRd rearrangements by manual
sequencing detection (Nyvold et al.,
2000). In addition, multiplex PCR of
cutaneous TCRb and TCRg gene re-
arrangements was performed according
to Biomedical and Health Research
Programme (BIOMED-2) guidelines
(van Dongen et al., 2003) and analyzed
with fluorescence fragment product
analysis on an automated capillary
electrophoresis DNA sequencer (Gen-
eScan; Applied Biosystems, Weiter-
stadt, Germany). PCR products were
purified and sequenced on an ABI
Prism 3100 Genetic Analyzer (Applied
Biosystems). Skin clonality in TCRg and
TCRb usage was detected in five and six
patients, respectively. On manual se-
quence analysis, two patients had
monoclonal patterns in BM. The BM
rearrangement (TCRd–V2D3) of patient
no. 4 was different from the cutaneous
rearrangements. One patient with a
polyclonal distribution in the skin had
identical clonal T cells in PB and BM
(Vg8–Jg1/2). These findings correlate
with reports of unrelated T-cell clones
in PB in up to 30% of patients with
MF, in benign lymphoproliferative
diseases, or occasionally in healthy
elderly donors (Delfau-Larue et al.,
2000; Beylot-Barry et al., 2001; Muche
et al., 2003).
Next, we wished to determine mini-
mal tumor infiltration using TCRg and
TCRb gene rearrangements identified in
the skin as clone-specific primers in
real-time quantitative PCR for the dis-
ease in PB and BM (Van der Velden
et al., 2003). Patient-specific PCR has
previously been used for molecular
diagnosis of cutaneous T-cell lympho-
mas (Lessin et al., 1991; Kono et al.,
1992; Veelken et al., 1995). The resolu-
tion power of conventional PCR tech-
niques is 1–5%, whereas clone-specific
real-time quantitative PCR enables the
detection of one malignant cell in up to
105 to 106 normal cells (van Dongen
et al., 2003). Six patients had suitable
clone-specific rearrangements in skin
samples. Primers covering as many
different genetic marker systems as
possible were designed for each patient
(Table 1). A modification of the guide-
lines for interpretation of real-time
quantitative PCR data in acute lympho-
blastic leukemia was used (van der
Velden et al., 2007). Results were
graded on a scale of 1–3 depending
on differences in the cycle threshold
value between the patients and poly-
clonal controls (Table 2). No patient
demonstrated a clear presence of neo-
plastic T cells in PB or BM (rating 1). An
indication of clonal cells (rating 2) was
achieved in three samples of PB and
BM, respectively. Only one patient had
rating 2 in both PB and BM. The rating
2 is comparable with criteria used in
studies in which false-negative results
must be prevented and positive results
due to non-specific amplification can-
not be excluded (van der Velden et al.,
2007). All patient specimens with rating
2 had only one of three replicates
positive and, with the exception of
one PB sample (patient no. 1), no
samples had rating 2 in more than one
of the applied genetic markers. Very
low levels of tumor infiltration make the
analysis less accurate and results shouldAbbreviations: BM, bone marrow; MF, mycosis fungoides; PB, peripheral blood
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be cautiously judged (van der Velden
et al., 2007). The cycle threshold values
in these assays were high (average 38.5
cycles (34.5–43.9)) and support very
low levels, if present at all. In addition,
skin samples were tested for SIL–TAL1
fusion gene transcripts to serve as
additional PCR targets (Pongers-Will-
emse et al., 1999). TAL1 deletions are
not present in normal cells but occur in
8% of cutaneous T cell lymphoma (Neri
et al., 1995). However, none were
detected in our study population.
Lymphomatous involvement in PB
has been determined by PCR and high-
resolution separation techniques in
9–36% of early-stage MF (Beylot-Barry
et al., 2001; Delfau-Larue et al., 2000;
Sibaud et al., 2003; Muche et al.,
2003). In BM, neoplastic cells identical
to those in skin and PB were demon-
strated by Sibaud et al. (2003) in 14%
(5/37) of stage I–IIA MF patients. We
speculated that increasing sensitivity
would enable the detection of systemic
disease in a higher proportion of
patients. An earlier report using a highly
Table 1. Clone-specific rearrangements
Junctional region nucleotide sequence
No.
Sex/age
(years) Stage
Clone-specific
rearrangements 50-Vc/Vb Nc/Nb Db Nb 30-Jc/Jb
1 M/56 T2N0M0 Vg9–Jg1.3/2.3 CTACTGTGCCTTGTG ATG AGAAACTCTT
IB Vb7.2–Db1–Jb2.4 GCCAGCAGCT CG GGGACAGGG TTG AACATTCAGT
Db1–Jb2.7 ACATTGTGGGGAC GAGAGA TACGAGCAGT
2 M/67 T2N0M0 Vg9–Jg1.3/2.3 CTACTACTGTGCCTTG AGCTTA AAGAACTCTT
IB Db1–Jb1.2 TGTAACATTGTGGGGAC CGATTGGGGGGT GGCTACACCT
3 M/84 T2N0M0 Vg2–Jg1.3/2.3 CCACCTGGGA GCAGGCC CTTTGGCAGT
IB Vg3/5–Jg1.3/2.3 CTGGGACAGG CGTGG TATTATAAGA
Vb15–Db2–Jb2.2 TGCCACCAGCAGA TCCAAC CGGGGGG CCGG CACCGGGGAG
4 M/73 T1N0M0 Vg9–Jg1.3/2.3 CCTTGTGGGA CCCCCCCCTTTT TTATTATAAG
IA Vg2–Jg1.1/2.1 CTGGGACGGG AATTTAAG GTGATTGGAT
Vb5.4–Db2–Jb2.1 AGCAGCTTGG AGT GGACTAGCGG CCTT TACAATGAGC
Db1–Jb2.4 GACAGGGG TCAG GCCAAAAACA
5 M/50 T3N0M0 Vg10–Jg1.1/2.1 TGCTGCGTGG GAACC ATACCACTGG
IIB Vg10–Jg1.1/2.1 TGCTGCGTGG GG CACTGGTTGG
Vb20.1–Db2–Jb2.1 GTGCTAGAGA TCT GGGG TT CTCCTACAAT
Vb5.8–Db1–Jb1.4 AGCAGCTTGG ACAGGG AGG TAATGAAAAA
6 M/43 T1N0M0 Vb19–Db1–Jb2.1 TCTGTGCCAG CAGCGCCA ACAGGG AGCTACG CAATGAGCAG
IA
Junctional sequences of the clonal TCRb and TCRg rearrangements in skin samples. Rearrangements targeted by clone-specific primers are in bold and are
underlined. M, male.
Table 2. Real-time quantitative PCR results
Peripheral
blood
Peripheral
blood
Bone
marrow
Bone
marrow
No. TCRb primer Rating TCRc primer Rating TCRc primer Rating TCRb primer Rating
1 V7.2–J2.4 3 V9–J1.3/2.3 2 V7.2–J2.4 3 V9–J1.3/2.3 3
D1–J2.7 2 D1–J2.7 2
2 D1–J1.2 3 V9–J1.3/2.3 3 D1–J1.2 3 V9–J1.3/2.3 3
3 V15–J2.2 2 V3/5–J1.3/2.3 3 V15–J2.2 3 V3/5–J1.3/2.3 3
4 V5.4–J2.1 3 V2–J1.1/2.1 V5.4–J2.1 3 V2–J1.1/2.1 3
D1–J2.4 3 2 D1–J2.4 3
5 V20.1–J2.1 3 NA — V20.1–J2.1 3 V10–J1.1/2.1 3
V5.8–J1.4 3 V5.8–J1.4 2
6 V19–J2.1 3 NP — V19–J2.1 2 NP —
Clone-specific primers are denoted by TCR gene rearrangement. The cycle threshold (Ct) value is defined
as the PCR cycle at which fluorescence exceeds a threshold for the first time and is directly proportional to
the amount of target sequence in the sample (Van der Velden et al., 2003). Rating 1: Clear presence of
clonal cells (X3 DCt from lowest background signal in all patient triplicates). Rating 2: Indication of
clonal cells (X1 DCt from lowest background signal in minimum one patient triplicate). Rating 3: No
detection of clonal cells (o1 DCt from lowest background signal in all patient triplicates or no
amplification detected at all). NA, no available patient material; NP, not possible to identify gene.
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sensitive (105) clone-specific RNase
protection assay detected lymphoma-
tous involvement in extracutaneous
samples otherwise cleared by micro-
scopic examination and conventional
PCR from two stage I MF patients
(Veelken et al., 1995). Nevertheless,
results from real-time quantitative PCR,
a technique more thoroughly tested for
the detection of minimal tumor infiltra-
tion, do not give solid evidence for a
systemic nature in our patient popula-
tion and do not offer further support to
the routine use of BM biopsies in early
disease staging. The fact that in patch/
plaque stage with good prognosis, T-
cell clonality is not detectable in
dermatopathic lymph nodes, typically
the first site of extracutaneous spread, is
in accordance with these results (Assaf
et al., 2005). We conclude that, if
present at all, the level of malignant T
cells in patients showing no signs of
disseminated disease by routine diag-
nostic procedures is so low that it
cannot be reliably detected by currently
available methods.
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